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Available online 5 January 2016Background: Antibiotic resistance is rising in important bacterial pathogens. Phage therapy (PT), the use of
bacterial viruses infecting the pathogen in a species-speciﬁc way, is a potential alternative.
Method: T4-like coliphages or a commercial Russian coliphage product or placebowas orally given over 4 days to
Bangladeshi children hospitalized with acute bacterial diarrhea. Safety of oral phage was assessed clinically and
by functional tests; coliphage and Escherichia coli titers and enteropathogenswere determined in stool and quan-
titative diarrhea parameters (stool output, stool frequency)weremeasured. Stool microbiotawas studied by 16S
rRNA gene sequencing; the genomes of four fecal Streptococcus isolates were sequenced.
Findings:No adverse events attributable to oral phage applicationwere observed (primary safety outcome). Fecal
coliphage was increased in treated over control children, but the titers did not show substantial intestinal phage
replication (secondary microbiology outcome). 60% of the children suffered from a microbiologically proven
E. coli diarrhea; the most frequent diagnosis was ETEC infections. Bacterial co-pathogens were also detected.
Half of the patients contained phage-susceptible E. coli colonies in the stool. E. coli represented less than 5% of
fecal bacteria. Stool ETEC titers showed only a short-lived peak and were otherwise close to the replication
threshold determined for T4 phage in vitro. An interim analysis after the enrollment of 120 patients showed no
amelioration in quantitative diarrhea parameter by PT over standard care (tertiary clinical outcome). Stool
microbiota was characterized by an overgrowth with Streptococcus belonging to the Streptococcus gallolyticus
and Streptococcus salivarius species groups, their abundance correlated with quantitative diarrhea outcome,
but genome sequencing did not identify virulence genes.
Interpretation: Oral coliphages showed a safe gut transit in children, but failed to achieve intestinal ampliﬁcation
and to improve diarrhea outcome, possibly due to insufﬁcient phage coverage and too low E. coli pathogen titers
requiring higher oral phage doses. More knowledge is needed on in vivo phage–bacterium interaction and the
role of E. coli in childhood diarrhea for successful PT.
Funding: The study was supported by a grant from Nestlé Nutrition and Nestlé Health Science. The trial was
registered with Identiﬁer NCT00937274 at ClinicalTrials.gov.
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In view of the growing threat of antibiotic resistance, WHO has
warned for a return into a pre-antibiotic era (Martinez, 2012). Alterna-
tives to antibiotics are thus urgently needed (Piddock, 2012; Stanton,
2013). Phage therapy (PT), the use of bacterial viruses (phages) against
pathogens, is a potentially attractive option for the prevention and treat-
ment of some bacterial infections (Sulakvelidze et al., 2001; Brüssow,
2005, 2012). Indeed, a large, randomized and placebo-controlled trial
conducted in children from Tbilisi/Republic of Georgia during the 1960sthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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with orally applied Shigella phages (Sulakvelidze et al., 2001). PT
was practiced in Poland in patients with antibiotic-resistant bacterial
infections on a case-by-case basis, apparently with high success
(Międzybrodzki et al., 2012). However, randomized controlled trials
(RCTs) in humans are needed to rationally assess the potential of PT. So
far, a single small RCT documented an effect in carefully selected patients
suffering from otitis externa (“swimmer's ear”) (Wright et al., 2009).
E. coli is an important cause of diarrhea in children from developing
countries (Qadri et al., 2005), resistant against many antibiotics (Jiang
et al., 2002) while efﬁcient E. coli diarrhea vaccines are not yet available
(Ahmed et al., 2013). Other than zinc and oral rehydration solution, no
speciﬁc, effective, safe and affordable treatment is available to reduce
the severity or duration of illness caused by this bacterial agent. We
hypothesize that oral administration of coliphage will be effective in re-
ducing severity of diarrhea in children with proven E. coli induced diar-
rhea. Therefore a RCT of PT with two different coliphage cocktails for
which safe use was demonstrated in healthy adults (Sarker et al.,
2012; McCallin et al., 2013) was performed in children with E. coli diar-
rhea. The primary endpoint was the safety of oral coliphage in children
infectedwith E. coli, the secondary endpointwas the titration of fecal co-
liphage and E. coli pathogen to assess in vivo lytic phage activity and the
tertiary endpoint was the impact of oral phage on quantitative diarrhea
parameters. Oral coliphage reached the intestine, but did not achieve
treatment effects over placebomost likely because intestinal E. coli titers
were low and close to the replication threshold of coliphages. Microbio-
ta analysis revealed amarked outgrowth of fecal streptococci during the
acute phase of diarrhea.
2. Methods
2.1. Participants and Study Design
A prospective, single center, randomized, placebo-controlled, parallel
group clinical trial was undertaken to assess the safety and efﬁcacy of
T4-like phage cocktail compared to Microgen ColiProteus phage cocktail
or placebo in 6–24-month-old male (to obtain stool without urine
contamination) children presentingwith acute onset of dehydrating diar-
rhea of less than 48hduration. The study tookplace at theDhakaHospital
of the International Centre for Diarrheal Disease Research, Bangladesh
(icddr,b) between June 2009 and September 2011. The trial was ap-
proved by the Research Review Committee and Ethical Review Commit-
tee of icddr,b (protocol #2008-062) and registered with the Identiﬁer
NCT00937274 at the ClinicalTrials.gov site. The study was performed ac-
cording to Good Clinical Practice and the Declaration of Helsinki (http://
www.who.int/bulletin/archives/79(4)373.pdf). Written informed con-
sent was obtained from parents or legal guardians of the child before
study enrollment. The T4 phage cocktail contained eleven T4-like phages
(AB2, 4, 6, 11, 46, 50, 55; JS34, 37, 98, D1.4) (Bourdin et al., 2014a,b). The
composition of the Microgen ColiProteus phage cocktail was described
previously by metagenome sequencing and electron microscopy
(McCallin et al., 2013). The placebowas reduced osmolarity oral rehydra-
tion solution (ORS) supplemented with zinc, the standard treatment for
uncomplicated watery diarrhea at icddr,b. The primary outcome of the
safety part of the study was the acceptability of the phage products by
the patients as determined by clinical observation and liver, renal and he-
matology tests described previously (Sarker et al., 2012; McCallin et al.,
2013). The secondary endpoint was the determination of coliphage and
total E. coli titers and their phage susceptibility in stool and the clearance
of ETEC from stool. The tertiary outcomewas changes in total stool output
(expressed as g/kg of body weight per day), frequency of stool (number/
day) and ORS need for rehydration (in ml/kg body weight per day) from
randomization to resolution of illness.
Children with at least four liquid stools during the previous 24 h,
with some degree of dehydration (WHO methodology) were consid-
ered for study enrollment after obtaining informed consent.2.2. Randomization
A random permuted block design (with block size of 6) (to equalize
the number of patients in the two treatment groups after short inter-
vals) was used for allocation of patients to the study interventions,
namely the two active products, i.e. T4 coliphage cocktail, Microgen
phage cocktail in ORS or placebo (0.9% NaCl) at a 1:1:1 ratio. The icddr,b
hospital pharmacist, not associated with the study in any other way,
prepared the products and handed it over to the study nurse unaware
of the product for dispensing to the patients following a computer-
generated list of random numbers developed by an independent
biostatistician not associated with the study. Code envelopes were
kept by the sponsor and by the investigator for un-blinding in emergen-
cy situations and after the blind reviewmeeting. The subjects, principal
investigator, hospital staff and laboratory personnel weremasked to the
treatment assignments. After mixing phage or placebo with ORS
powders in 30mlmineralwater (Vittelmineralwater, pH7.6, bicarbon-
ate 384 mg/l) and a food dye, the interventions products were indistin-
guishable. The study products were given 3 times per day (8 am, noon,
4 pm) for four days.
2.3. Power Calculation
We estimated the sample size based on stool output. In a previous
trial at icddr,b in childrenhospitalizedwithuntreated ETEC and EPEC di-
arrhea we observed a stool output of 176+ 100ml/kg body weight in a
4-day period (Casswall et al., 2000). With an anticipated 30% reduction
in stool volume,we estimated a sample size of 71 at 5% signiﬁcance level
and 80% power. To adjust for a 5% drop-out rate, we decided to enroll
225 children into the trial. Note that the interim analysis was done
with 120 patients, 53% of the planned enrollment.
2.4. Procedures
Following conﬁrmation of the absence of rotavirus in stool by ELISA
and Vibrio by dark ﬁeld microcopy, and sending stool samples for fur-
ther microbiological assessments, i.e. Salmonella, Shigella, Aeromonas
and Campylobacter according to standard procedures at icddr,b (Harris
et al., 2008) and for identiﬁcation of ETEC, EPEC or EAEC by multiplex
PCR assay using speciﬁc primers as described (Svenungsson et al.,
2000), the enrolled childrenwere randomized to intervention. Children
with systemic infection, invasive diarrhea, severe acute malnutrition
(weight for height z score b −3SD of WHO median or presence of
edema), signiﬁcant medical abnormalities and who had received or
needed antibiotic treatment were excluded. Initial correction of dehy-
drationwas performedusinghypo-osmolarORS solution or initial intra-
venous rehydration solution (for children with severe dehydration)
followed by ORS solution, equal to the amount of abnormal (watery or
liquid) stool loss, until diarrhea resolves.
Children whose fecal culture identiﬁed other bacterial enteric path-
ogens or no E. coli pathogen remained in the study and their data were
used for Intention-to-Treat (ITT) analysis. Sub-group analysis was done
for conﬁrmed E. coli infection. Freshly passed stool was obtained daily at
about 4 pm (the time was kept ﬁxed as the ﬁrst dose was fed exactly at
4 pm) for quantitative colony counts of E. coli on EMB and MacConkey
agar plates, total bacterial count by qPCR (Nadkarni et al., 2002) andmi-
crobiota analysis. Three putative E. coli colonies from day 1 stool agar
plates were tested for sensitivity to the applied phage cocktails at
NRC, Switzerland.
The nursing staff recorded the frequency, consistency and volume of
stool and urine passed every six hours (to a sensitivity of 1 g). This was
achieved through a combination of placing the subject on a cholera cot
and collecting urine in a pediatric urine collection bag. The data collect-
ed from this procedure was also used to calculate amounts of ORS solu-
tion required to account for ﬂuid losses due to diarrhea. Stool frequency
was counted by the study nurse and consistency of every stool passed
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formed or soft or no stool produced during two consecutive 6-hour pe-
riods were used to estimate the duration of diarrhea. Feeding appropri-
ate for age was introduced early as ad libitum breastfeeding (for breast
fed children) or formula feeding (for non-breast fed children) or
standardized hospital diet to provide approximately 100 kcal per kg
body weight per day.
If diarrhea continued beyond ﬁve days, treatment was judged a fail-
ure and the child was transferred to the general ward of the hospital for
furthermanagement following the hospital's standard protocol. Resolu-
tion of illnesswas deﬁned as passage of formed or soft stools during two
consecutive six-hour periods. Patient follow-up visit occurred 21 days
after ﬁrst dose.
Safety evaluation of patients included, in addition to clinical observa-
tion, chemistry tests which comprised liver and renal function assays
and hematology tests that were done at the admission and discharge
from the hospital as described previously (Sarker et al., 2012; McCallin
et al., 2013).
2.5. Phage Detection
One gram of stool sample was resuspended in TS (8.5 g NaCl and 1 g
tryptone/l) to a ﬁnal volume of 5 ml and centrifuged for 15 min at
14,500 ×g. The cleared supernatant was ﬁltered through a Millex
AP20 preﬁlter followed by a 0.45 μm pore size Minisart ﬁlter. The
presence of phages was determined on two indicator strains: E. coli
strain WG5 obtained from J. Jofre, University of Barcelona (Spain), a
common indicator strain used in phage ecology studies (Guzmán
et al., 2008), and E. coli strain K803, a K-12 derivative lacking prophage
lambda, obtained from E. Kutter, Evergreen College, Olympia, WA, USA.
This strain lacks restriction-modiﬁcation genes and contains only the
core part of the lipopolysaccharide making it susceptible to a wide
range of coliphages (Chibani-Chennouﬁ et al., 2004). The strains were
propagated in Hershey broth supplemented with casein-derived
amino acids (15 g/l). Phages were enumerated using the double layer
plaque assay, with top agar at 7.5 g/l on a bottom layer of 15 g agar/l
in broth (Chibani-Chennouﬁ et al., 2004). Phage dilutions were
prepared in TS: 100 μl of stool ﬁltrate and 100 μl of an exponentially
growing bacterial culture weremixed together, incubated at room tem-
perature for 15 min and used to inoculate 3 ml of top agar. Plates were
incubated over-night at 37 °C and phage plaques were counted. Phage
titer was calculated for plaque forming units (pfu) per g stool.
2.6. Stool Microbiota Analysis
Total DNA was extracted using the QIAamp DNA Stool Mini Kit
(QIAGEN), following the manufacturer's instructions, except for the
addition of a series of mechanical disruption steps (11 × 45 s) using a
FastPrep apparatus and Lysing Matrix B tubes (MP Biochemicals) as
described (Junick and Blaut, 2012).
The 16S variable region V1 to V3 was PCR ampliﬁed and sequenced
on Roche 454 GS-FLX-Titanium Sequencer as described (Sanchez et al.,
2014) Raw sequence data were deposited in the GenBank Short Read
Archive (Accession number: SRP067629) and analyzed using Mothur
v.1.33.0 and QIIME v.1.8 software packages (Schloss et al., 2009;
Caporaso et al., 2010). Pyrosequencing reads were denoised with the
Mothur implementation of PyroNoise (Quince et al., 2009) according
to the 454 SOP (Schloss andWestcott, 2011). Chimeras were identiﬁed
using usearch61 in QIIME (Edgar et al., 2011). The sequences were then
trimmed as described in theMothur 454 SOP in order to keep sequences
overlapping the same 16S region. OTUs de novo picking at 97% identity
was performed using uclust in QIIME (Edgar, 2010). Taxonomy assign-
ment of OTU representative sequences used the RDP Classiﬁer in
QIIME with conﬁdence threshold of 0.6 on the Greengenes reference
database v.13.8(Simeoni et al., 2015). At species level, the taxonomic as-
signment was determined by BLAST (Altschul et al., 1990) using thewebsite http://blast.ncbi.nlm.nih.gov with a 97% identity threshold. Di-
versity analyses were performed in QIIME, Mothur and Calypso (http://
bioinfo.qimr.edu.au/calypso/). Dirichlet Multinomial Mixture analysis
was performed in Mothur as described (Ding and Schloss, 2014).
Figures were created with GraphPad Prism version 6.07 for Windows
(GraphPad Software, La Jolla California USA) and Microsoft Excel 2010.
2.7. Genome Sequencing
Individual bacterial colonieswere isolated from fecesona Streptococcus-
enriching agar, characterized as streptococci by API fermentation
gallery (API 20 STREP, bioMérieux, France) and four colonies identiﬁed
as Streptococcus by 16S rDNA sequencing, three derived from different
diarrhea patients and one derived from a local age-matched control
child, underwent whole genome sequencing.
Genomic DNA was extracted from mid-exponential cultures using
Gentra DNA Purgene kit (Qiagen). 10 Kb librarieswere prepared follow-
ing Paciﬁc Biosciences (PacBio) protocol. Sequencingwas performed on
the PacBio RS platformusing C2/C2 chemistry and four single-molecule-
real-time (SMRT) cells were used per strain with a 120 min collection
protocol. The sub-reads were de novo assembled using the PacBio
Hierarchical Genome Assembly Process (HGAP)/Quiver software pack-
age (Chin et al., 2013). The HGAP workﬂow consists of three steps:
Preassembly to generate long and highly accurate sequences; assembly
of the long and highly accurate sequences using Celera assembler andﬁ-
nally, Consensus Polishing using the Quiver algorithm to derive a highly
accurate consensus for the ﬁnal assembly.
The strains were assembled into one to three contigs. The results of
the sequencing and assemblies are summarized in Suppl. Table 1. The ge-
nomes were annotated using the NCBI Prokaryotic Genomes Automatic
Annotation Pipeline (PGAAP) and have been deposited at GenBank
(NCBI) under accession numbers CP0113688 and CP013689 for isolates
S1 and S5 (1 contig) and LPVQ00000000 and LPVR00000000 for isolates
S3 and S6 (2–3 contigs). Plasmid DNA was not sequenced by our ap-
proach, but plasmids were not detected in the sequenced strains.
A global alignment of chromosomes was plotted using MUMMER
package (nucmer parameters: –maxmatch-c 20-g 0-b 1-l 20–
noextend). The KSNP phylogenetic tree was built with KSNP3 tool
(Gardner and Hall, 2013) with the following parameters: –k 13–ML.
2.8. Genomic Safety Analysis
In order to reduce the complexity, sequence reads for the four strep-
tococcal genomes showing 100% sequence identity were removed from
the total reads to generate a set of non-redundant (nr) reads. This set of
reads was investigated for virulence factors in three ways. First, the
reads were mapped against closely related streptococci with proven
(Streptococcus gallolyticus) and suspected (Streptococcus lutetiensis) vir-
ulence genes. Matches weremanually investigated by additional BlastX
searches to verify the annotations from the deposited and the newly
sequenced streptococci. Second, the nr reads were mapped against all
genes present in an in-house Database for Undesirable Genes described
previously (Denou et al., 2009). Third, the nr reads were screened
against two public databases compiling antibiotic resistance genes
(ARDB) (Liu and Pop, 2009) and bacterial virulence factor genes
(VFDB) (Chen et al., 2012). Only hits having two or more reads aligned
and coveringmore than 30% of the genewere considered as positive hits
and were further investigated.
2.9. Statistical Analysis
Outcome variables, e.g., stool output (g/kg × d), and ORS Intake
(ml/kg × d) were compared among the groups using one-way analysis
of variance (ANOVA) and between the groups using student's t test.
Confounders, e.g., age, duration of diarrhea before hospitalization, and nu-
tritional status were adjusted using multivariate analysis (multiple
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distribution were normalized by log transformation, and the t test was
applied on transformed data. The Wilcoxon's rank test was used for
skewed data that cannot be normalized by transformation.
3. Results
Four hundred children hospitalizedwith acutewatery diarrheawere
screened for this study; 280 were excluded mainly for rotavirus (n =
251) or Vibrio diagnosis (n = 12); 120 fulﬁlled the entrance criteria
andwere randomized: 41 receivedplacebo (saline)with standard treat-
ment (ORS plus zinc) (P), 40 received orally 1.4 × 109 pfu of the
Microgen ColiProteus (McCallin et al., 2013) cocktail (M) and 39
children received 3.6 × 108 pfu of the Nestlé Research Centre (NRC)
T4-like coliphage cocktail (T) in addition to standard treatment
(Sarker et al., 2012; Bourdin et al., 2014a,b). Fig. 1 shows the study
ﬂow chart.
3.1. Safety Analysis
Per protocol a safety analysis was done after enrollment of 75 pa-
tients. No observations indicative of a Jarisch–Herxheimer reaction
(Yang et al., 2010) were seen (Table 1). Liver, kidney and hematological
functions were normal when using standard tests (Sarker et al., 2012;
McCallin et al., 2013). One T4 phage and one placebo recipient
developed generalized tonic–clonic convulsion a few hours after the
initial product application, which was attributed by the clinician to
hyponatremia and acidosis associated with diarrhea.
3.2. Lack of Clinical Efﬁcacy of Oral Phage
At enrollment, children in the three groups did not differ for prior
duration of diarrhea, stool frequency, or vomiting (Table 2). At an inter-
im analysis with 120 enrolled and 115 evaluated children, no signiﬁcant
difference was seen between the groups when evaluating quantitative
diarrhea criteria (stool frequency, stool weight, oral rehydration solu-
tion needed to correct dehydration) (Fig. 2A–C) (P N0.1 for all compar-
isons, t test). In the acute phase, we observed lower means for stool
weight in T compared to M; T also happened to have a higher percent-
age of E. coli-positive cases than M and P (Fig. 1). However, even when
limited to proven E. coli infections, oral phage had no signiﬁcant impactFig. 1. Study ﬂow chart. The numbers indicate the childrenwith diarrheawhowere screened, en
patients with V. cholerae positive stool in darkﬁeldmicroscopy; others, patientsmeeting other e
T4, phage cocktail consisting of T4-like phages fromNRC; LAMA, left the study against medical a
patient without a pathogenic E. coli in the stool.on quantitative diarrhea criteria (Table 3). Four days after admission,
50%of the childrenwere discharged from thehospital (no difference be-
tween the groups). The increase in quantitative diarrhea values seen at
day 5 in Fig. 2 reﬂects therefore enrichment for children with more
severe diarrhea. At day six, 93, 88, and 84% of patients treated with T,
M or P, respectively, had recovered from diarrhea (difference not
signiﬁcant, t test).
3.3. Detection of Fecal Phage
Oral Microgen, and to a lesser extent the T4 phage cocktail, resulted
in a signiﬁcantly higher fecal phage prevalence and titer than seen in
placebo recipients likely producing endogenous phage (Chibani-
Chennouﬁ et al., 2004) (Fig. 2 D, E). No patient showed higher fecal out-
put than oral input. Electron microscopy done for the ﬁrst 56 patients
with sensitivity to detect 106 viral particles per g stool (Goldsmith and
Miller, 2009) demonstrated only few phage particles in three patients
excluding substantial in vivo replication of oral phage (data not shown).
Fecal coliphage titers did not differ signiﬁcantly between patients
with diagnosed ETEC or EPEC/EAEC infection or patients lacking a
diarrheagenic E. coli (Suppl. Fig. 1A). In addition, fecal phage titers
were not higher in patients harboring a phage-sensitive E. coli colony
in the stool (50% of all patients) compared to patients lacking such
colonies (three random colonies were tested per patient, Suppl.
Fig. 1B) suggesting passive transit of oral phage through the gut.
In the plaque assay T4-like and T7-like coliphages can be differenti-
ated by plaque size (Suppl. Fig. 2A–C). If a differential survival or repli-
cation occurred for these phages in the gut, one would expect a shift
in relative proportion from the 1:1 ratio seen for T4 and T7 phages of
the M cocktail (McCallin et al., 2013) in the stool of recipients of this
cocktail. No such shift was observed (Suppl. Fig. 2D).
3.4. Etiology of Diarrhea
Stool series from theﬁrst 56 patients underwent detailed clinicalmi-
crobiology analysis (Harris et al., 2008; Svenungsson et al., 2000): 77%
yielded an E. coli pathogen by culture and subsequent pathotype analy-
sis (ETEC: 23; EAEC: 10; enteropathogenic (EPEC): 2; mixed E. coli: 8
patients).
The presence of E. coli virulence genes was corroborated for these 56
patients by PCR (Vidal et al., 2005) on whole stool DNA. ETEC-speciﬁcrolled and evaluated. Rota(+ve), patients with rotavirus positive stool in ELISA; DF(+ve),
xclusion criteria; Microgen, commercial ColiProteus phage cocktail fromMicrogen, Russia;
dvice; PP, per protocol, E. coli+, patient displaying a pathogenic E. coli in the stool; E. coli-
Table 1
Physical examinations in children hospitalized with diarrhea at admission and after four days of treatment with the allotted phage or placebo product.
Treatment T4-phage Microgen phage Placebo
Time Adm Day 4 Adm Day 4 Adm Day 4
n 25 23 26 20 27 23
Age, month 10 ± 3.2 (8.8–11.3) 12 ± 4.1 (10.4–13.6) 13 ± 4.8 (11.2–14.8)
Weight, kg 8.1 ± 1.3 (7.6–8.6) 8.0 ± 1.3 (7.5–8.5) 8.4 ± 1.4 (7.9–8.9) 8.3 ± 1.5 (7.6–9.0) 8.4 ± 1.5 (7.8–9.0) 8.2 ± 1.7 (7.5–8.9)
Temp, °C 36.9 ± 0.5 (36.7–37.1) 36.7 ± 0.5 (36.5–36.9) 36.7 ± 0.6 (36.5–36.7) 36.5 ± 0.4 (36.3–36.7) 36.9 ± 0.8 (36.6–37.2) 36.8 ± 0.7 (36.5–37.1)
Pulse/min 119 ± 7 (116–122) 118 ± 4 (116–120) 121 ± 5 (119–123) 118 ± 5 (116–120) 120 ± 6 (118–122) 119 ± 5 (117–121)
Respiration/min 33 ± 6 (31–35) 31 ± 2 (30–32) 32 ± 5 (30–34) 30 ± 3 (29–31) 34 ± 3 (33–35) 32 ± 2 (31–33)
BP systolic (mmHg) 89 ± 6 (87–91) 86 ± 5 (84–88) 89 ± 6 (87–91) 87 ± 5 (85–89) 88 ± 5 (86–90) 87 ± 5 (85–89)
BP diastolic 54 ± 5 (52–56) 53 ± 4 (51–55) 56 ± 6 (54–58) 52 ± 3 (51–53) 57 ± 8 (54–60) 55 ± 4 (53–57)
n, number of children per investigated group. Values are means ± standard deviations (95% CI).
No signiﬁcant differences were seen between clinical parameters at admission and 4 days of phage or placebo treatment in diarrhea patients in paired t-tests. However, T4-phage treated
children were signiﬁcantly younger than placebo recipients (P = 0.01 in t-test), but did not differ from Microgen phage treated children.
128 S.A. Sarker et al. / EBioMedicine 4 (2016) 124–137genes were detected in 28 (23 elt+est+; 3 elt+; 2 est+); EPEC in 5
(4 eae+bfp+; 1 eae+); EAEC (daaD+) in 7 patients for at least 2 succes-
sive stool samples. Stool samples were also cultured for other bacterial
pathogens (Harris et al., 2008). Campylobacter jejuni, Campylobacter
coli, Aeromonas, Vibrio cholerae, Salmonella, and Shigella ﬂexneri were
detected in 9, 2, 2, 2, 1 and 1 patients, respectively. All but two also
harbored an E. coli pathogen. Electron microscopy of putative viral pel-
lets from these 56 stools identiﬁed one patient infected with rotavirus,
which apparently escaped ELISA detection of group A rotavirus.
3.5. Fecal E. coli Titers
Total fecal bacterial counts as determined by real time PCR
(Nadkarni et al., 2002) were signiﬁcantly lower in patients than in
controls (P b 0.001 in Dumm test) (Fig. 3A). Viable E. coli colony counts
represented only 5% of all fecal bacteria in diarrhea patients (Fig. 3B)
and were at most 10-fold higher in E. coli as compared to non-E. coli
diarrhea patients (median viable stool E. coli titers were 5 × 108 cfu/g
stool for ETEC, 2 × 108 for EAEC/EPEC patients and 5 × 107 for patients
without E. coli diarrhea diagnosis).
The titer of heat-stabile (Fig. 3C) and heat-labile (Fig. 3D) enterotox-
in genes were investigated over the course of diarrhea by real time PCR
(Guion et al., 2008). By calibration against an elt+est+ E. coli strain of
known titer, the data were expressed as cfu ETEC per g stool. Median ti-
ters were low, but the titers were widely spread. When limited to
microbiologically conﬁrmed ETEC infections, peak median titers of
3 × 107 ETEC cfu/g stool were observed on day 2 of hospitalization
with rapid decline over the next days (Fig. 3C, D). Most children with
microbiologically deﬁned EPEC or EAEC infection and healthy controls
had enterotoxin gene counts below the detection limit of the test,
conﬁrming the speciﬁcity of the test. No signiﬁcant decrease was seen
for ETEC titers as assessed by real time PCR of heat-labile and heat-
stable enterotoxin genes in phage-treated patients compared to the
placebo recipients (P N 0.1, t test) (Fig. 4).
3.6. Fecal Microbiota Composition by 16S rDNA Sequencing: Transient
Streptococcus Overgrowth
We determined the microbiota composition in daily collected
stool samples for the ﬁrst 56 patients enrolled into the trial by 454Table 2







Placebo 41 8.70 ± 1.7 (8.2–9.2) 32.1 ± 10.3 (29.0–35.
Microgen phages 40 8.43 ± 1.4 (8.0–8.9) 33.1 ± 10.4 (32.5–33.
T4-like phages 39 8.36 ± 1.3 (8.0–8.8) 32.6 ± 10.2 (29.4–35.
Values are means ± standard deviation (numbers in parenthesis denote 95% CI).
Two-tailed P values in unpaired Student t-tests N0.19 for all comparisons.sequencing of PCR-ampliﬁed 16S rDNA using universal bacterial
primers (Sanchez et al., 2014) and compared it with the microbiota
composition in stools sampled at the same time period from 20 age-
matched healthy control children (median age 11 months) living in
the same city under comparable socioeconomic conditions. During the
ﬁrst day of hospitalization, fecal Streptococcus represented a signiﬁcant-
ly higher abundance in diarrhea patients than in healthy controls (P =
0.001, Fisher's exact test); Escherichia was higher in patients than in
controls, but not signiﬁcantly so (P = 0.06) (Fig. 5A). Control children
showed a higher stool abundance of Biﬁdobacterium than diarrhea pa-
tients in the acute phase (P= 0.003). Over the next days of hospitaliza-
tion, a gradual increase in Biﬁdobacterium and a concomitant decrease in
Streptococcus abundance were observed (Fig. 5A, P = 0.008). This shift
from Streptococcus to Biﬁdobacterium during the hospital stay was
seenwhether the sequence analysiswas based onmean (Fig. 5A) orme-
dian abundance (Fig. 6A–C) or whether the analysis was based on the
V123 (all presented data in the current report) or on the V456 regions
(data not shown) of the 16S rRNA gene. When further differentiated
for the diarrhea pathogen, the decrease in fecal Streptococcus abundance
during hospitalization was clearer for patients with EPEC and EAEC in-
fections or diarrhea without E. coli pathogen than for ETEC patients
(Fig. 6D, E). Subjects with elevated Escherichia abundance had ETEC,
but not EPEC/EAEC infections (Fig. 6C, F). Children with non-E. coli
diarrhea (Fig. 6F) and healthy controls (Fig. 6C) showed with few
exceptions b1% Escherichia abundance.
The heatmapof correlationbetweenbacterial genera showed a strong
anti-correlation between Biﬁdobacterium and Streptococcus while only a
weak anti-correlation between Biﬁdobacterium and Escherichia was ob-
served (Fig. 7A). No signiﬁcant difference was observed for microbiota
composition and temporal development of the stool microbiota between
placebo andphage recipientswhen all patientswere considered (data not
shown). Evenwhen limited to patientswith proven ETEC infection, only a
difference of borderline statistical difference was seen for microbiota
composition (not involving Escherichia) between placebo and T, but not
M phage recipients (Suppl. Table 2).
When the 16S rRNA gene sequence data were analyzed at the spe-
cies level (Fig. 5B), fecal streptococci (van den Bogert et al., 2013)
were categorized into two groups, namely the S. gallolyticus/lutetiensis
(Schlegel et al., 2003) and the Streptococcus salivarius groups, with
very few S. infantis calls. These were the same streptococcal speciesre 1st dose Stool frequency/day before 1st
dose
No of vomiting/day before 1st
dose
2) 16.0 ± 7.1 (13.8–18.2) 5.9 ± 4.7 (4.5–7.3)
7) 14.6 ± 6.5 (12.6–16.6) 6.4 ± 5.7 (4.6–8.2)
8) 16.0 ± 7.6 (13.6–18.4) 7.7 ± 7.2 (5.4–10.0)
Fig. 2.Oral phages reach the intestine in children hospitalizedwith acute bacterial diarrhea, but showno impact on quantitative clinical diarrhea outcomes. Left:Mean and standard deviation for
stool weight (measured without urine contamination) in g/day (A), stool frequency per day (B), and need for oral rehydration solution in ml/day to correct dehydration (C) for the
speciﬁed day of hospitalization in children enrolled into the three treatment groups identiﬁed by the color code. No signiﬁcant difference was detected between the treatment groups.
Right, D: Prevalence of phage positive stools (≥10 pfu/g stool on E. coli indicator strain K-12) at the indicated time points (D01–05: days 1 to 5 of hospitalization; D21: re-convalescent
visit 21 days after hospital admission) in the three treatment groups; green: NRC T4-like phage cocktail (T), red: Russian Microgen phage cocktail (M), blue: placebo (P). E: Titer
distribution and median fecal phage titer in log10 pfu/g stool for the indicated treatment groups.
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children. Likewise, the same Biﬁdobacterium groups, namely B. longum,
B. kashiwanohense, B. biﬁdum and B. catenulatum group, were detected
both in diarrhea patients and healthy controls (Fig. 5B).
3.7. Streptococcal Abundance Correlates With Diarrhea Symptoms
Two observations associated Streptococcus abundance with diarrhea
symptoms in the enrolled patients. First, an increase in Streptococcus
abundance was observed in patients at day 5 of hospitalization
(Fig. 5A). Since 50% of the initially enrolled patients were discharged
from the hospital at day 4, these subjects representedmore severely af-
fected patients as also seen for quantitative diarrhea parameters at day
5 (Fig. 2C). Interestingly, a fecal microbiota difference was alreadyobserved in the early phase of hospitalization between patients later
staying for 4 (short hospitalization) or 5 days (long hospitalization) in
the hospital: children with an earlier diarrhea resolution also showed
an earlier normalization of the Biﬁdobacterium/Streptococcus ratio and
a lower Escherichia percentage than children with a later diarrhea reso-
lution (day 5 or later) (Fig. 5C).
Second, whenwe plotted the diarrhea stool output of a patient during
hospitalization against the Streptococcus abundance in the stool microbi-
ota, we observed a positive correlation. This correlation was signiﬁcant
when all patients, only ETEC patients (Fig. 7B) or diarrhea patients with-
out an E. coli infectionwere analyzed. Notably,Biﬁdobacterium stool abun-
dance showed a signiﬁcant negative correlation with diarrhea stool
output (Fig. 7C). Escherichia abundancedidnot correlatewith stool output
(data not shown).
Table 3
Quantitative diarrhea parameters in patients with microbiologically conﬁrmed E. coli diarrhea treated with Microgen or T4-like phage cocktail or placebo.
Conﬁrmed E. coli infections (n = 69) Day 1 Day 2 Day 3 Day 4
Stool frequency:
Placebo (n = 19) 7.5 ± 3.4 (6.0–9.0) 6.0 ± 3.1 (4.6–7.4) 6.3 ± 4.5 (4.3–8.3) 4.8 ± 3.9 (3.0–6.6)
Microgen (n = 22) 6.3 ± 4.1 (4.6–8.0) 5.3 ± 2.9 (4.1–6.5) 4.2 ± 2.5⁎ (3.2–5.2) 4.6 ± 5.1 (2.5–6.7)
T4-like phage (n = 28) 6.6 ± 4.1 (5.1–8.1) 5.8 ± 4.3 (4.2–7.4) 5.0 ± 3.9 (3.6–6.4) 4.3 ± 3.2 (3.1–5.5)
Stool weight:
Placebo (n = 19) 514 ± 444 (314–714) 422 ± 360 (260–584) 350 ± 352 (192–508) 316 ± 280 (190–442)
Microgen (n = 22) 433 ± 265 (322–544) 276 ± 196 (194–358) 278 ± 213 (189–367) 293 ± 279 (176–410)
T4-like phage (n = 28) 406 ± 480 (228–584) 344 ± 321 (225–463) 280 ± 284 (175–385) 280 ± 345 (152–408)
ORS need:
Placebo (n = 19) 393 ± 261 (276–510) 341 ± 341 (188–494) 333 ± 319 (190–476) 283 ± 373 (115–451)
Microgen (n = 22) 328 ± 220 (236–420) 252 ± 294 (129–375) 192 ± 256 (85–299) 216 ± 280 (99–333)
T4-like phage (n = 28) 330 ± 289 (223–437) 281 ± 368 (137–425) 293 ± 438 (131–455) 201 ± 312 (85–317)
Values are means ± standard deviation (95% CI, conﬁdence interval).
Days 1–4 of treatment.
Stool frequency: number of bowel movements per day for the indicated day of hospitalization.
Stool weight: stool weight in g per patient and the indicated 24 h period.
ORS: volume of ORS in ml needed per indicated day to correct dehydration.
n = number of patients per speciﬁed group.
⁎ P = 0.07 in unpaired Student t-test, for all other comparisons P N 0.1.
Fig. 3. Total bacteria, E. coli and enterotoxigenic E. coli titer development in serial stool samples of hospitalized children during an episode of acute diarrhea. A. Median titer with interquartile
range for total stool bacteria determined by real time qPCR with universal bacterial 16S rDNA primers; expressed as log10 cfu/g stool equivalents for healthy local control children
(H) and diarrhea patients at the indicated day after hospital admission. Only H is signiﬁcantly different from the other time points (Dumm's multiple comparisons tests). B. Median
with interquartile range of viable E. coli counts on MacConkey agar determined as log10 cfu/g fresh stool (ordinate) for the indicated day of hospitalization of diarrhea patients (no
signiﬁcant difference). C and D. Titer distribution and median titers for heat-stable (st-ETEC, C) and heat-labile (lt-ETEC, D) enterotoxin-carrying bacteria in the stool of diarrhea
patients hospitalized with a microbiologically conﬁrmed ETEC infection. Titers determined by real time PCR are for the indicated days of hospitalization and are compared to healthy
control children (H). The titers are expressed as log10 median titers in ETEC cfu equivalents.
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Fig. 4.No oral phage treatment effect on fecal ETEC titers. Titer distribution andmedian titers for heat-labile (lt, left) and heat-stable (st, right) enterotoxin gene-carrying ETEC bacteria in the
stool of diarrhea patients treatedwith placebo (P), Microgen phage (M) orNRC T4 phage (T). Titers were determined by real time PCR for the indicated day of hospitalization (D01 toD05)
and the return visit (D21). Titers in healthy control children (H) are given for comparison. The titers are expressed as log10 titers in ETEC cfu equivalents.
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Streptococci were isolated from the stools of three diarrhea patients
and identiﬁed by API fermentation gallery and 16S rDNA sequencing as
S. gallolyticus (strains S1, S3) or S. infantarius (strain S5). Their genome
length was 1.8 to 2.05 Mb and represented by a single (S1, S5) or 2
contigs (S3) (Suppl. Table 1). Their genomes were closely related to
each other as well as to the sequenced Streptococcus strain S6 isolatedFig. 5. Fecal microbiota analysis by 16S rRNA gene sequencing in serial stool samples from children
samples from 20 healthy control children (H) and 56 diarrhea patients at the indicated day of h
bacterial genera identiﬁed by the color code at the right. B. Bacterial community structure at spe
are displayed for relative abundance at species level deﬁned by the color code at the right. S. sal
S. equinus, S. pasteurianus, S. gallolyticus, S. macedonicus, S. alactolyticus and S. porcorum are m
B. ruminantium, B. merycicum, B. adolescentis, B. dentium, and B. stercoris are members
B. kashiwanohense group. C. Bacterial community structure for 56 diarrhea patients that we
hospitalization. The panel gives the mean relative abundance in percent for the bacterial generfromahealthy control child (Fig. 8A). These genomeswere closely related
to sequenced strains of the S. bovis/S. equinus species complex to which
also belong food-associated species (S. pasteurianus, S. macedonicus),
commensal species (S. infantarius, S. equinus) and facultative pathogens
(S. gallolyticus) (Fig. 8B). By phylogenetic tree analysis based on single nu-
cleotide polymorphisms ofwhole sequenced genomes (Gardner andHall,
2013) S5 and S6 were placed close to S. infantarius, S1 associated with
S. macedonicus, S3 with S. gallolyticus (Fig. 8C). More distantly relatedhospitalized with acute bacterial diarrhea. A. Bacterial community structure proﬁles for fecal
ospitalization (D01–D21). The panel gives the mean relative abundance in percent for the
cies level. Healthy controls (H) and diarrhea patients at the speciﬁed day of hospitalization
ivarius and S. vestibularis are members of the S. salivarius group. S. lutetiensis, S. infantarius,
embers of the S. gallolyticus group. B. catenulatum, B. pseudocatenulatum, B. angulatum,
of the B. catenulatum group. B. kashiwanohense and B. breve are members of the
re hospitalized for 4 day (S—short stay) or 5 days (L—long stay) at the speciﬁed day of
a identiﬁed by the same color code as in panel A.
Fig. 6. Succession of the three major bacterial genera in the gut microbiota during recovery from diarrhea.Median percentage with interquartile range and distribution for the individual
patients with respect to Biﬁdobacterium (A and D), Streptococcus (B and E) and Escherichia (D and F) contribution to the stool microbiota at the indicated day of hospitalization. In A to
C data are presented for all investigated diarrhea patients; in D–F, patients were separated with respect to etiology (ON: other bacterial pathogens than E. coli and no pathogens
detected; PA: EPEC and EAEC; T: ETEC infections) compared to healthy local controls (H).
132 S.A. Sarker et al. / EBioMedicine 4 (2016) 124–137streptococci belonged to the S. salivarius complex comprising oral
commensals (S. salivarius) and dairy strains (S. thermophilus) and
S. pyogenes, a human pathogen (Fig. 8B, C).
The S1 chromosome is with a length of 2′052 kb 298 kb shorter than
the clinical S. gallolyticus isolate UCN34 isolated from an endocarditis
patient (Danne et al., 2011). When using BlastN 80% of S1 chromosome
aligns to UCN34 chromosome with an identity of 80% bp identity or
more. On the dotplot (Suppl. Fig. 4A), we can see 2 large loci that are
absent from S1 chromosome. Locus 1 is approximately 47 kb long (56
prophage genes), and Locus 2 is approximately 60 kb long (71 genes)
and comprises the pilus geneswhichwere biologically proven virulence
genes of this endocarditis isolate (Danne et al., 2011). Locus 3 is speciﬁc
to S1 chromosome and is 53.5 kb long.
Our isolates were also closely related to S. lutetiensis strain 0033
(Suppl. Fig. 4B) identiﬁed in Chinese childrenhospitalizedwith diarrhea
for which no known enteropathogen could be identiﬁed (Jin et al.,
2013). The Chinese researchers proposed numerous virulence factors
in their isolate, some were shared by our isolates (Suppl. Table 3).
However, upon reinvestigation, alternative annotations were found for
them that question their role as virulence genes.
3.9. Fecal Microbiota Association With Diarrhea
When the three major fecal bacterial genera were analyzed for the
transition period from acute diarrhea into recovery, neither Escherichia
nor Streptococcus showed a clear association with this transition. We
found low abundance of Escherichia in the acute phase of EPEC/EAEC di-
arrhea patients and a high Streptococcus persistence into the recovery
phase in ETEC patients. A high Streptococcus abundance was also seen
in some healthy controls (Suppl. Fig. 4). The Dirichlet Multinomial
Mixture modeling (Holmes et al., 2012) classiﬁed the investigated
stool samples in four distinct partitions (“fecal community types”)displayed as a bubble plot in Fig. 9A and described in Suppl. Table 4.
The genera Biﬁdobacterium and Streptococcus are by far themost impor-
tant contributors to the differences in community structures of the
partitions (37 and 31%, respectively), followed by Escherichia and
Dorea (4% each) (Suppl. Table 5). Partition 3, which is characterized by
a very high abundance of Biﬁdobacterium (mean = 90.6%) and a low
abundance of Streptococcus (4%), was the dominant community type
in control children. This community typewas lower in diarrhea patients
during the acute phasewith a trend for increasewith recovery (Fig. 9B).
Partition 4, which is themost variable partition (Suppl. Table 4) is char-
acterized by a high abundance of Streptococcus (68.5%) combined with
either elevated amounts of Escherichia (4.9%) or a reduced amount of
Biﬁdobacterium (16.0%). Compared to controls partition 4was increased
in all diarrhea patients over the hospitalization period (Fig. 9B), and this
was independent of diarrhea etiology (data not shown). Partitions 2
and 1 showed medium Biﬁdobacterium (58.2 and 46.6%, respectively),
elevated Streptococcus (34.4 and 16.0%), and small, butwidely distribut-
ed Dorea (in partition 1= 7.7%) and very low Escherichia (0.8 and 2.3%,
respectively) abundance— this combined constellation was foundwith
comparable abundance in both diarrhea patients and controls while
partition P1 on its own increased with recovery from diarrhea
(Fig. 9B). Notably, partition 4 gradually decreased with recovery from
diarrhea (Fig. 9B), as if fecal streptococci develop a pathological poten-
tial only in the presence of Escherichia or if not counter-acted by
biﬁdobacteria.
4. Discussion
In the current PT trial, T4-like phages were chosen for safety con-
cerns (Sarker et al., 2012). T4-like coliphages are obligate lytic viruses,
their genomes are well characterized and devoid of bacterial virulence
genes and they were propagated on a safe production strain (E. coli K-
Fig. 7. Anti-correlation between Streptococcus and Biﬁdobacterium abundance in the feces and their association with stool output in diarrhea. Heat map of correlation between the indicated
bacterial genera identiﬁed in the stool of diarrhea patients (A). The strength for correlation and anti-correlation is given in the color key at the top left. Correlation between percentage
of Streptococcus (B) or Biﬁdobacterium (C) in fecal microbiota (abscissa) and stool weight in g/day (ordinate) for patients hospitalized with ETEC diarrhea. Correlation coefﬁcients and
their P value are given at the top of the panels.
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et al., 2009). However, the in vivo replication potential of T4 was previ-
ously only explored in mice where it was found to be inferior to T7
phage (Weiss et al., 2009). Whether the prolonged T7 phage excretion
is an advantage for PT over the shorter elimination time of T4 phage
(Bruttin and Brüssow, 2005) is currently unclear. The commercial
Russian phage cocktail consisted of at least 17 different phage types in-
cluding T7 phage (McCallin et al., 2013). The Microgen recipients
showed indeed a higher fecal phage titer than T4 recipients, but they
did not show a higher prevalence of T7 over T4 in the stool. The higher
fecal output in the M recipients is partly explained by a higher oral
phage input.
In acute cases of E. coli diarrhea, the barrier function of the gut mu-
cosa in the small intestine is compromised. When the pathogen is
lysed by phage, in vivo released endotoxins and enterotoxins can thus
potentially cross into the circulation. However, no systemic reaction to
endotoxin was observed (Yang et al., 2010) which is not surprising
since no signiﬁcant in vivo replication of the phage was seen, hence no
signiﬁcant lysis of cells with concomitant toxin release had occurred.
While oral coliphages as virions are safe in diarrhea patients, it is still
unclear whether oral phages are safe when acting as infectious virus
lysing the E. coli target cell in the gut of diarrhea patients.
Neither the T4-like nor the Russian coliphage cocktail showed a clin-
ical beneﬁt over standard care in terms of stool output, stool frequency
or rehydration. This observation should be interpreted with caution
since it could still represent a false-negative outcome because at interim
analysis only half of the planned patients were enrolled. The reported
trial was thus not powered to detect a treatment effect, but only toassess safety issues and to gain a mechanistic insight into PT. Notably,
we did not observe a substantial in vivo replication of the orally applied
phage which is a basic requirement for PT. Despite a careful screening,
only 60% of the 120 enrolled patients harbored an E. coli pathogen in
the stool. E. coli is thus a less frequent cause of diarrhea (18% of all
screened patients) than we had anticipated for Bangladeshi children
(36% of all screened patients) (Albert et al., 1999). Furthermore, even
in microbiologically deﬁned E. coli diarrhea less than 5% of the total
fecal bacteria were E. coli. When only ETEC pathogens were counted, a
median titer of 105 cfu ETEC per g stoolwas detected.With an estimated
in vivo burst size of 10 (Brüssow, 2013), no phage ampliﬁcation beyond
106 pfu/g stool was therefore expected, which is close to the observed
peak fecal phage titers. That a microbiologically deﬁned E. coli diarrhea
was not characterized by high intestinal pathogen titers can also be
deduced from the observation that ETEC and EAEC infections in the
present study showed only 10-fold higher fecal E. coli titers than diar-
rhea patients lacking an E. coli pathogen. Likewise, careful quantitative
PCR analysis in stools from Peruvian children with EPEC diarrhea
showed titers of 3 × 105 EPEC/g stool which were just 10-fold higher
than EPEC titers in healthy controls (Barletta et al., 2011). Since the
in vitro replication threshold for T4 phage on a laboratory indicator
E. coli strain was determined to 103 cfu/ml (Wiggins and Alexander,
1985), the pathogenic E. coli titer in conﬁrmed cases of E. coli diarrhea
might simply not be high enough to sustain phage replication in vivo.
From our data it is impossible to predict what percentage of the
diarrheal episodes is caused by E. coli. Only a minority of the screened
children had an E. coli diarrhea by standard tests. Even less showed a
high fecal abundance of E. coli by molecular tests and stool titrations.
Fig. 8. Genome comparisons for the isolated and sequenced fecal streptococci. A: Dotplot alignment of the genome from S. gallolyticus fecal isolate S3 (y-axis) against S. infantarius isolate S5,
S. galloyticus isolate S1, and S. infantarius isolate S6 (x-axis) obtained from three different patients and one control (S6) at theDNA sequence level. B: Dotplot alignment of the genome from
the fecal S. infantarius isolate S5 (y-axis) against streptococcal strains of the database at the DNA sequence level. The following genomeswere chosen for comparison (from left to right on
the x-axis): S. pyogenes (human pathogen), S. macedonicus (dairy strain), S. gallolyticus (human pathogen), S. infantarius (dairy strain), S. pasteurianus (human gut commensal), S. equinus
(horse gut commensal), S. salivarius (oral commensal), and S. thermophilus (dairy strain) (from left to right). C: Phylogenetic tree analysis based on single nucleotide polymorphisms of the
indicated sequenced genomes with the kSNPv2 software (Gardner and Hall, 2013). The position of the four sequenced fecal streptococci is indicated by the boxes S1, 3, 4, and 5 next to
representative streptococci marked with their identiﬁer.
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group could be responsible for diarrhea in children. However, to over-
come limitations for future phage therapy trials, we strongly recom-
mend to control ﬁrst and foremost whether the targeted pathogen
occurs with sufﬁcient titers to support in vivo phage replication.
There are still other limitations which have to be considered when
interpreting the negative clinical outcome of the present study. Only
half of the patients contained phage-sensitive E. coli colonies in the
stool. The Russian phage cocktail was obviously not customized to the
regional patients and we had to adapt our T4 phage cocktail to the
ecological situation in Bangladesh to achieve a reasonable coverage
(Bourdin et al., 2014b). Since the phages were isolated several years
before the start of the trial, a constant adaption of the phage cocktail
to the prevailing ecological situation is needed. However, it is not clear
whether phage coverage was indeed the limiting factor in the current
trial since the phage susceptibility of the stool isolates did not correlate
with fecal phage titers. Both phage preparations were given without
antacid. Buffering of gastric acidity by a slightly alkaline mineral water
was perhaps too weak and an additional dose of bicarbonate as recom-
mended by the commercial suppliermight have increased phage transit
through the stomach. Since it would also increase the risk of nosocomial
cross-infection in a diarrhea hospital, such a treatmentwas excluded for
ethical reasons. However,we do not believe that pharmaceutic formula-
tion of the phage was a limiting factor in the current trial since children
have a higher (more alkaline) stomach pH than adults. Indeed, in previ-
ous trials sensitive biologicals were given to children with diarrhea
(antibodies, probiotics), which were recovered intact from the feces
(Hilpert et al., 1987) or achieved clinical effects in Bangladesh (Sarkeret al., 1998, 2005). However, a higher oral phage dose might be desir-
able since children in Bangladesh showed a less good fecal bioavailabil-
ity of phage than adults from Switzerland (Bruttin and Brüssow, 2005)
suggesting some loss during gastrointestinal passage.
Regarding the lack of in vivo susceptibility of E. coli to coliphages,
several factors need consideration. Prominent are physical barriers for
phages to reach E. coli (increased peristalsis in diarrhea, reduced
phage diffusion rate in mucus layer, pathogen protection in bioﬁlms)
or slow growth rate of bacterial cells in the stationary phase (Brüssow,
2013). It will be important to study E. coli-phage interaction in vivo
with animal experiments. However, E. coli does not induce diarrhea in
small laboratory animals and infections with Citrobacter rodentium in
mice, commonly used as a surrogate, are not a suitable model system
since it induces a colitis (Collins et al., 2014). Experiments in animals
like piglets or calves which suffer naturally from E. coli infection in the
small intestine and diarrhea (Fairbrother et al., 2005) are clearly
needed.
Another important limitation of our study is the question whether
our observations in the fecal samples representwhat is happeningwith-
in the gut. From an analytical viewpoint it would be desirable to analyze
bacteria andphages in samples from theupper small intestine. ETEC and
EPEC infections occur in the upper parts of the gut and the bacteria ex-
creted with stool might not any longer be in the same growth phase as
in the small intestine (stationary vs. logarithmic growth). However,
such sampling is invasive and ethically difﬁcult to justify in a normally
self-limiting disease in children. Again, dissection experiments in exper-
imentally infected and phage-treated pigsmight provide the needed in-
sight. In fact, data from pig have supported the “kill-the-winner”model
Fig. 9. Fecal Community Type analysis in the diarrhea patients and healthy controls.A. A DirichletMultinomialMixturemodeling deﬁned four partitions P1 to P4 (“fecal community types”) in
the investigated stool samples. Each vertical line of the bubble plot represents one individual stool sample, each horizontal line represents a bacterial genus identiﬁed at the right ordinate.
The size of the squares indicates the percentage of 16S rRNA gene sequences represented by this genus in the given stool sample (code at the lower left corner). B. The relative percentage
of partitions P1 to P4 is given for all 56 investigated diarrhea patients for the indicated day of hospitalization (day D01 to 05) and the return visit (day D21) in comparison with
age-matched local healthy controls (H).
135S.A. Sarker et al. / EBioMedicine 4 (2016) 124–137of phage–bacterium population dynamics also for the gut ecosystem
(Allen et al., 2011) suggesting that high titers of target bacteria are
needed for PT.
ETEC showed only a short-lived stool peak titer which corresponds
to recent reports describing in adult cholera patients from Bangladesh
an even shorter peak titer of V. choleraemaintained for just 6 h (Hsiao
et al., 2014). Curiously, the peak titer of ETEC occurred on the second
day of hospitalization as if ETEC was not the cause for hospital admis-
sion. In fact, the role of E. coli as a pathogen has recently been challenged
for its low pathogenicity index. Only certain E. coli pathotypes in select-
ed age groups of children and geographical areas were by this criterion
signiﬁcantly linked with diarrhea (Taniuchi et al., 2013; Liu et al., 2014;
Kotloff et al., 2013). In fact, E. coli diarrhea in children from developing
countries is increasingly considered as a polymicrobial infection
(Taniuchi et al., 2013; Kotloff et al., 2013) aswas also seen in the present
study.
Microbiota analysis by 16S rRNA gene sequencing conﬁrmed that
only a small fraction of the stool microbiota from children hospitalized
with a microbiologically diagnosed E. coli diarrhea were represented
by Escherichia. At admission, the dominant stool bacteria were fecal
streptococci independently whether ETEC, EAEC or non-E. coli diarrhea
caseswere considered. Comparisonwith healthy local controls suggestsamarked streptococcal dysbiosis in the acute phase of diarrhea. Notably,
the relative abundance of streptococci was positively correlated with
stool output, it predicted the length of diarrhea duration and in EAEC
or non-E. coli diarrhea it decreased with the resolution of diarrhea. Is a
fecal streptococcal dysbiosis thus a potential biomarker for diarrhea?
Since all these observations apply to the average of the studied popula-
tion and not to individuals, who showed great variation, this marker is
of limited use for the clinicalmicrobiologist. However, fecal streptococci
diagnosed as S. salivarius also represented a prominent part of the acute
diarrhea microbiota in adult cholera patients from Bangladesh (Hsiao
et al., 2014). E. coli diarrhea in adults and children from Bangladesh
showed an ordered gut microbiota succession and fecal streptococci
belonged to this sequence (David et al., 2015). In the GEMS survey chil-
dren from Bangladesh displayed a signiﬁcant increase in fecal strepto-
cocci during diarrhea. This was, although at lower level, also observed
in African children (Pop et al., 2014). Are fecal streptococci therefore
candidate new enteropathogens as suggested by Chinese researchers
(Jin et al., 2013)? This is unlikely for four reasons: ﬁrst, using efﬂuents
from ileostoma patients, fecal streptococci of the S. bovis complex
have been identiﬁed as typical small intestine commensal in humans
(Booijink et al., 2010). Fecal streptococci are fast-growing, efﬁcient fer-
menters of simple carbohydrates (van den Bogert et al., 2013) possibly
136 S.A. Sarker et al. / EBioMedicine 4 (2016) 124–137allowing a transient outgrowth when competing gut bacteria are
purged from the gut by increased peristalsis in diarrhea. Second, no
diarrhea-relevant virulence geneswere detected in the three sequenced
genomes of fecal streptococci isolated fromdiarrhea patients. Notably, a
biologically proven virulence (pilus) gene identiﬁed in a S. gallolyticus
isolated from an endocarditis patient (Danne et al., 2011) was not de-
tected in the stool isolates. Third, an increased abundance of
S. gallolyticus was also seen in colon cancer patients (Boleij and
Tjalsma, 2013). Bacteria of the S. gallolyticus species complex might ad-
here to the chronically (colon cancer) or transiently (diarrhea) injured
gut mucosa. Interestingly, the replacement of the streptococci by fecal
biﬁdobacteria occurs with the same kinetics as the repair of the gutmu-
cosa with newly synthesized enterocytes. Finally, the analysis of the
fecal microbial community types showed that elevated fecal Streptococ-
cus abundance had no pathogenic potential as long as they are counter-
balanced by an elevated Biﬁdobacterium abundance. This could mean
that our understanding of diarrhea etiology will have to change in the
future: not only need quantitative pathogen titers to be determined,
pathogen constellations and pathogens interactions with commensal
bacteria need to be considered for the understanding of diarrhea. In
our dataset, loss of biﬁdobacteria was in fact the best biomarker for
diarrhea.
Based on these considerations and the presented microbiological
and clinical observations, we decided to stop the PT trial at interim anal-
ysis. In summary, while phage therapy is still one very important alter-
native tool against antibiotic resistance, we need to understand in detail
the in vivo interactions between phage and its host bacterium to judge
the reliability and efﬁcacy of such approaches. At the moment it is
risky to conclude whether phage therapy is or is not a viable option
against antibiotic-resistant bacterial pathogens.
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